Cucea R
C.M.D.T.A Acad. St. Milcu, Bucuresti.
Oftalmologia. 2006;50(3):38-43.
The present-day glaucoma therapy is aiming to preserve visual function by decreasing the intraocular pressure below a certain level, that prevents the optic nerve damage to occur. The target IOP must be individualized, considering the IOP level at presentation, the severity of the optic nerve damage, life expectancy and associated risk factors. In order to prevent the glaucoma progression, the more serious the damages are at presentation, the lower the target IOP level must be. New ocular hypotensive agents that have been created during the last few years allowed a more efficient control of the glaucoma progression.
当今的青光眼治疗旨在通过将眼压降低到一定水平来保护视功能,从而防止视神经损伤的发生。目标眼压必须个体化,要考虑就诊时的眼压水平、视神经损伤的严重程度、预期寿命及相关危险因素。为了防止青光眼进展,就诊时损伤越严重,目标眼压水平就必须越低。过去几年研发的新型降眼压药物能更有效地控制青光眼进展。